



# DIA BioVenture Day

Is the Current Bioventure Paradigm  
Delivering Return for Patients, Investors  
and the Health Care System?

28 March 2017 | Crowne Plaza Glasgow, UK



VENTURE  
CAPITAL

## Get a different perspective on the funding of Innovative Care!

### WHY ATTEND?

#### Are you from Pharma R&D or Business Development?

- You will hear and discuss whether highly parallel but small step innovation is sustainable for both Pharma R&D and re-imburement. Latest research on behalf of the European Parliament has investigated the links between Pharmaceutical R&D Models and Access to Affordable Medicines.

#### Are you from a small or medium sized Biotech Company?

- You will get deep insights into Europe's Biotech-ecosystem and its infrastructural and funding challenges. Also get latest information about evolving funding models and true pipeline opportunities for unmet medical need.

#### Are you an Investor or Venture Capitalist in the biopharma space?

- You will hear the views of Regulators, Payers, Policy Makers, and Patients on the value of current innovation in health care.

**Benefits for all attendees** will include plenty of networking opportunities between senior health care stakeholders in a unique gathering.

### SPECIAL FEATURES OF THE CONFERENCE

- A uniquely broad representation of health care stakeholders such as BioVenture companies, investors and venture capitalists, regulators & policy makers, payers, patients, and big pharma convene on the trusted and neutral DIA Platform.
- Achieve a broad perspective of the challenges that development & re-imburement of health care innovation poses onto modern societies. We will explore this in two large panel discussions:
  - Hepatitis C: Expensive cure vs. life-long suffering & health care expenses.
  - Immuno-oncology: therapeutic break through area or nightmare for health care funding?
- Moderated poster discussion during the networking evening

### WHO WILL YOU MEET?

CXO, business development heads, and R&D leaders of biotech companies and big pharma; leading biotech hub staff, academia / university spin-offs; venture capitalists; health care insurers; investment bankers; fund managers; business and financial analysts; patient advocates; regulators; policy makers; payers; foundations.

### PROGRAMME COMMITTEE

#### Holger G Adelman

Senior VP and Managing Director, DIA  
EMEA, Switzerland

#### Dimitrios Athanasiou

Patient Advocate, Muscular Dystrophy  
Association Hellas  
Board Member in UPPMD and EMA  
Patient Expert for DMD, Greece

#### Helga RübSamen-Schaeff

Chair of the Board, AiCuris, Germany

#### Julia Schüler

Owner, BioMedServices, Germany

### PROGRAMME ADVISORS

#### David Haerry

Patient Advocate, Member of Board of  
Directors, European AIDS Treatment  
Group, Switzerland

#### Joep Muijers

Partner, LSP, USA

## LEARN MORE

Visit [www.DIAglobal.org/BioVentureDay](http://www.DIAglobal.org/BioVentureDay) for programme updates  
or contact [Holger.Adelmann@DIAglobal.org](mailto:Holger.Adelmann@DIAglobal.org) with questions.



# DIA BioVenture Day | Tuesday, 28 March

08:00 REGISTRATION AND WELCOME COFFEE

08:30 WELCOME REMARKS

**Holger G Adelman**, Senior VP and Managing Director, DIA EMEA, Switzerland & **Kerry Sharp**, Head Scottish Investment Bank, UK

08:45 KEY NOTE

## SUCCESS FACTORS FOR BRINGING A PRODUCT TO THE MARKET

**Helga Rübnsamen-Schaeff**, Chair of the Board, AiCuris, Germany

09:10 SESSION 1

## HEALTH SYSTEM FINANCING AND REIMBURSEMENT OF INNOVATION

Session 1 will set the scene for most of the day by exploring key challenges that the Biotech-ecosystem, Pharmaceutical Innovators, and ultimately the Patients that are expecting innovative cures are facing nowadays. Key stakeholders from the Biotech Industry, Regulatory/Payer area, and Research in the Economic & Scientific Policy field will share their recent insights and perspectives.

### Europe's flawed and underfunded Biotech-ecosystem (EBE position paper)

**Barbara Freischem**, Executive Director, European Biopharmaceutical Enterprises (EBE), Belgium

### Is Parallel Micro-Innovation Overburdening the Health Care System?

**Luca Pani**, SAWP and CHMP Member, former AIFA, Italy

### Links between Pharmaceutical R&D Models and Access to Affordable Medicines

**Wija Oortwijn**, Partner / Manager Sector Health, Ecorys (lead researcher of a recent EU Parliament publication), The Netherlands

10:40 COFFEE BREAK

11:00 SESSION 2

## INNOVATIVE FUNDING MODELS

Session 2 will review innovative ways to fund private and public enterprises and to ensure patients with rare diseases are not being forgotten. Experienced Investors will share different approaches to fund innovative cure.

### Funding Private & Public Enterprises

**Joep Muijers**, Partner, Life Science Partners, USA

### Deutsche Börse Venture Network (Growth Financing Network by Deutsche Börse Group / German Stock Exchange)

**Oliver Mahr**, Investment & Fintech Hub Manager, Deutsche Börse Venture Network, Germany

### The Venture Philanthropy Model in Drug Development - The Vision DMD Case Study

**Emily Crossley**, co-founder and joint CEO, Duchenne, UK

### Megafunds: Concept Introduction & Discussion

**Dimitrios Athanasiou**, Duchenne Patient Advocate; Patient expert, European Medicines Agency, European Union

12:30 PRESENTATION & DISCUSSION

### EMA Health Care Pipeline White Spots Analysis – Opportunities for Bio-Ventures?

**Agnès Saint Raymond**, Head of International Affairs, European Medicines Agency, European Union

This presentation & discussion will be a rich source of inspiration for all health care stakeholders.

13:15 LUNCH

14:00 CASE STUDY PANEL DISCUSSION

## HEPATITIS C: EXPENSIVE CURE VERSUS LIFE-LONG SUFFERING AND HEALTH CARE EXPENSES

Moderator: **Helga Rübnsamen-Schaeff**, Chair of the Board, AiCuris, Germany

Panellists:

**Regulator and Payer View:** **Luca Pani**, SAWP and CHMP Member, former AIFA, Italy

**Academia View:** **John Dillon**, Professor of Hepatology, Dundee University, UK

**Venture Capitalist Perspective:** **Joep Muijers**, Partner, Life Science Partners, USA

**Industry View:** Representative invited

**Patient View:** **Tamas Bereczky**, Communications Officer, European AIDS Treatment Group, Hungary

**HTA Body View:** **Ailsa Brown**, Lead Health Economist, Scottish Medicines Consortium, UK

**Payer View:** **Menno Aarnout**, Executive Director, AIM, Belgium

15:30 COFFEE BREAK

16:00 CASE STUDY PANEL DISCUSSION

## IMMUNO-ONCOLOGY: THERAPEUTIC BREAK THROUGH AREA OR NIGHTMARE FOR HEALTH CARE FUNDING

Moderator: **Duane Schulthess**, Managing Director, VitalTransformation, Belgium

Panellists:

**Regulator View:** **Tomas Salmonson**, Chair CHMP, Senior Scientific Advisor Medical Products Agency, Sweden

**Clinical View:** **Stefan Symeonides**, Edinburgh Cancer Research Centre, UK

**Product Partnership Perspective:** **Wolfgang Stoiber**, Managing Director, JSB-Partners, USA

**Biotech View:** **Mariola Soehngen**, CEO, Mologen, Germany

**Companion Diagnostics View:** **Kamala Maddali**, Cancer Genetics Inc., USA

**Big Pharma View:** **Luca Morlotti**, Exec. Dir, Regional Market Access EMEAC Oncology, MSD International GmbH, Switzerland

**Patient View:** **Bettina Ryll**, Founder, Melanoma Patient Network Europe, Sweden

**HTA Body View:** **Alan Macdonald**, Vice Chair, Scottish Medicines Consortium, UK

**Payer View:** **Menno Aarnout**, Executive Director, AIM, Belgium

17:30 NETWORKING RECEPTION & MODERATED POSTER DISCUSSION

Poster Moderators: **Joep Muijers**, Partner, Life Science Partners, USA & **David Haery**, Member of Board of Directors, European AIDS Treatment Group, Belgium

Topics for posters:

- BioVenture success stories
- BioVenture hurdles and how to overcome them
- New BioVenture Business Plans

19:30 END OF THE EVENT

CATEGORY	Member *	Non-Member*
Industry	€ 800.00 <input type="checkbox"/>	€ 955.00 <input type="checkbox"/>
Government/Charitable/Non-profit/Academia (Full-Time)	€ 400.00 <input type="checkbox"/>	€ 555.00 <input type="checkbox"/>
<p>Take advantage of a special flat rate and register for the 29th Annual EuroMeeting For more information and detailed programme visit <a href="http://www.DIAglobal.org/EM2017">www.DIAglobal.org/EM2017</a></p> <p><input type="checkbox"/> I would like to register for the 29th Annual EuroMeeting   ID#17101BVD <span style="float: right;">€ 1,890.00 <input type="checkbox"/></span></p>		
<p>If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee. Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to availability. Please contact DIA EMEA for more information. Registration fee includes: refreshments, lunches, reception and meeting materials.</p> <p style="text-align: right;"><b>TOTAL AMOUNT DUE: € _____</b></p>		

\*All fees are subject to the applicable VAT. Payment due 30 days after registration and must be paid in full by commencement of the event.

## ATTENDEE DETAILS

PLEASE COMPLETE IN BLOCK CAPITAL LETTERS OR MAKE REGISTRATION EVEN SIMPLER BY ATTACHING THE ATTENDEE'S BUSINESS CARD HERE

Prof  Dr  Ms  Mr

Last Name

First Name

Company

Job Title

Address

Postal Code  City

Country

Telephone

Fax

Email

Please provide your European VAT number

## DIA MEMBERSHIP

Join DIA now to qualify to save on future events and to receive all the benefits of membership. Visit [www.DIAglobal.org](http://www.DIAglobal.org) and click on Membership for more details.

DIA offers one year complimentary membership against event registration at non-member rate

I do not want complimentary membership

## TERMS AND CONDITIONS

### Cancellations

All cancellations must be in writing and received at the DIA EMEA office by 17:00 CET on 24 February 2017 and will be subject to an administrative fee:

Full Meeting Cancellation: Industry (Member/Non-member) = € 200.00  
Academia/Charitable/Government /Non-profit (Member/Non-member) = € 100.00  
Tutorial cancellation: € 50.00

For cancellations after this date, or if the delegate fails to attend the meeting, no refund of fees will be given and be responsible for the full registration fee. DIA EMEA reserves the right to alter the venue and dates if necessary. If an event is cancelled, DIA EMEA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

### Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA EMEA office of any such substitutions as soon as possible.

### Photography and Video Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

### Exhibit Hall Access

The EuroMeeting registration includes access to the Exhibit Hall Wednesday to Friday during opening times. DIA does not allow access to the Exhibit Hall to anyone under the age of 18.

The DIA Europe, Middle East & Africa Contact Center will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET.

Email [emea@DIAglobal.org](mailto:emea@DIAglobal.org)

Tel. +41 61 225 51 51

Fax +41 61 225 51 52

Web [www.DIAglobal.org](http://www.DIAglobal.org)

Mail DIA EMEA, Kuechengasse 16, 4051 Basel, Switzerland

## PAYMENT METHODS

**Credit cards:** Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

Please charge my  VISA  MC  AMEX

Card N°

Exp. Date

Cardholder's Name


**Bank transfers:** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Course ID#17101 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe, Middle East and Africa.**

By signing below, I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking [here](#).

Date	Signature
------	-----------

# DIA 29TH ANNUAL EUROMEETING GLASGOW | 2017 29-31 MARCH



TRANSLATIONAL HEALTH CARE | **FROM BENCH TO BEDSIDE - AND BACK**

## 10 Themes to Build Your EuroMeeting Experience

- Theme 1: Globalisation of Global Product Health Care Development - What are the Current Successes and Challenges?
- Theme 2: Innovation of Global Product Health Care Development - What are the Key Success Factors?
- Theme 3: Current Challenges in Clinical Research
- Theme 4: eHealth/Big Data/Master- and Reference Data Management
- Theme 5: Pharmacovigilance
- Theme 6: Regulatory Science
- Theme 7: Medical Devices and Combination Products
- Theme 8: HTA, Value and Access
- Theme 9: Information on Medicines, Medical Writing and Dossier Generation
- Theme 10: Special Populations

**2,500+**  
PARTICIPANTS

**REGISTER  
TODAY**

**120+**  
EXHIBITING  
COMPANIES



### DIAMOND Sessions

- Major European Regulatory Science Challenges
- Current Trends and Solutions in Global Clinical Operations
- Global Regulatory Convergence
- Clinical Development Partnering 2.0

To download the programme and to register visit  
[DIAGlobal.org/EM2017](http://DIAGlobal.org/EM2017)